GTO ID | GTC3540 |
Trial ID | NCT05984927 |
Disease | Age-Related Macular Degeneration |
Therapy | Gene transfer |
Treatment | NG101 |
Phase | Phase1|Phase2 |
Recruitment status | Recruiting |
Title | A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration |
Year | 2023 |
Country | Canada |
Company sponsor | Neuracle Genetics, Inc |
Other ID(s) | NG101WA-01 |
Vector information | |||||
|
Cohort1: dose level 1 | |||||||
|
|||||||
Cohort2: dose level 2 | |||||||
|
|||||||
Cohort3: dose level 3 | |||||||
|